BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $34 to $36.
BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $34 to $36.